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C5
ECONOMIC ASPECTS OF
ACUTE LIMB ISCHAEMIA
Compared with the management of critical limb
ischaemia, the investigations and treatments of ALI
have been subjected to very few economic analyses,
possibly because of the urgency and the limited
number of therapeutic options. The economic data
on amputation is presented in Economic Aspects of
Critical Limb Ischaemia, D 5, P 5232.
The health care costs of treating an occlusion in an
isolated native peripheral artery were estimated by
Janosik et all and Ourielet al,2 from several retro-
spective series of patients treated with either throm-
bolytic therapy, with urokinase or streptokinase, or
surgical thrombectomy. Only the costs of the initial
admission were included, and hospital charges were
used as a proxy for costs. Comorbid conditions were
not documented. The most striking results are the
convergence of economic data calculated between
1990 and 1993 that show similar mean charges.
These range from $20,000 (EUR 18,600) to $26,000
(EUR 24,180) for all three treatments. Patients treat-
ed with urokinase have shorter length of stay but
higher drug charges. However, the relevance of the
comparison is limited by the fact that these were ret-
rospective studies. Thus, it appears that when con-
sidering different strategies for thrombectomy, cost
is not a decision criterion.' A similar figure of
$25,000 (EUR 23,250) for thromboembolectomy was
found by Hoch et al 4 in 1994, who reported higher
costs of $45,000 (EUR 41,850) and worse results
when urokinase was used as well in the procedure.
Lower costs of surgical revascularisation were found
by Singh et al in a 1993 to 1995 study in the United
Kingdom. Their $6,617 (EUR 6,154) cost per patient
included the cost of the initial procedure and a 12-
month follow-up," This study did not compare sur-
gery with other treatments.
Thus, the choice between surgery and thromboly-
sis for ALI should not be based on economic factors
but rather on predicted best clinical outcome. This is
because both treatments have similar hospital costs
in one study, whereas surgery is the better option in
terms of results and lower costs from another study.
(See Results of Surgical and Endovascular
Procedures for Acute Limb Ischaemia, C 4.4, P 5132,
for analysis of the conflicting data comparing
catheter-directed thrombolysis and surgery for
ALI.)
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Critical Issue 26: Economic data on acute limb
ischaemia
There is a need for prospective studies document-
ing the costs of treating patients with acute limb
ischaemia. To add significant data to this field,
future studies should
• Define the duration and severity of ischaemia
• Specify the aetiology (thrombus/embolus)
• Prospectively compare, with randomisation, the
therapeutic options
• Document the use of resources (see
Recommendation 7)
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CLINICAL TRIAL ISSUES IN ACUTE LIMB
ISCHAEMIA
The appropriate treatment of acute limb ischaemia is
difficult to extract from the literature. This is because
of individual or institutional reports of the results of
both surgical and thrombolytic treatment either con-
taining bias or not comparing with concurrent con-
trols or not using standardised reporting practices. It
is also because several recent trials comparing these
two modalities have, in retrospect, been seen to have
serious flaws. Conversely, now that these are appar-
ent, guidelines for future trials can be developed
that should further clarify the proper selection of
patients for treatment and the treatment of choice in
specific settings. The following are some of the criti-
cal issues in designing a trial in ALI, with examples
of the problems that have been encountered in the
past.
